In conclusion, in addition to strengthening the DNA of normal cells and breaking the DNA of NSCLC cells, HMGB1 gene therapy can reverse the cisplatin resistance of Cis-R NSCLC cells by reducing cytoplasmic HMGB1. This evidence concerns the gene HMGB1 and non-small cell lung carcinoma.